Ask My Investor AI
Public company · NYSEPublished company research
OGN

Identity verified against SEC EDGAR filing 0001628280-26-011125; registered as Organon & Co., CIK 0001821825.

Organon

Organon is mapped to the Women's health formalization theme as Women's-health products - contraception (Nexplanon implant), Jada System (postpartum hemorrhage), fertility, plus biosimilars and established (legacy) brands.. High by design - Organon was established as a women's-health-focused company (2021 Merck spin-off) - but a large share of revenue comes from established brands and biosimilars rather than the core women's-health growth engine. Current-quarter women's-health franchise revenue was not retrieved this session. Its latest filing reports $6.22 billion of revenue (FY2025). Theme materiality is stated separately and, where not independently verified, is marked accordingly.

Ask follow-up research
Reviewed company research · researched 2026-07-22 · not an individual investment recommendation
Listing
public
Ticker
OGN
Exchange
NYSE
HQ
—
Currency
USD
SEC CIK
0001821825
Investment case

How this company captures the theme economics

Competitive position

High by design - Organon was established as a women's-health-focused company (2021 Merck spin-off) - but a large share of revenue comes from established brands and biosimilars rather than the core women's-health growth engine. Current-quarter women's-health franchise revenue was not retrieved this session. Company-specific competitive positioning is assessed at the theme level and awaits deeper primary research.

Scarce assets

Scarce assets in this value chain include reimbursement and coverage decisions (state ivf/fertility mandates, employer benefit design, cms/medicaid) - the gating variable for the whole theme., specialist capacity: reproductive endocrinologists/fertility clinics, urogynecology, maternal-fetal medicine., proprietary clinical data and validated assays/algorithms (nipt content, hpv assays, ai mammography)..

Products, segments, and customers

Organon operates in Women's health formalization. Segment- and product-level detail is pending company-specific research.

Theme capture

High by design - Organon was established as a women's-health-focused company (2021 Merck spin-off) - but a large share of revenue comes from established brands and biosimilars rather than the core women's-health growth engine. Current-quarter women's-health franchise revenue was not retrieved this session.

Conditions

What must be true

  1. Latest quarterly women's-health revenue (Nexplanon growth trajectory, Jada uptake), fertility contribution, LOE exposure and debt profile.
  2. The exposure described for Organon must be confirmed as financially material in official filings.

Identifiable catalysts

  • Forthcoming quarterly and annual issuer filings
  • Theme-level catalysts detailed in the Women's health formalization brief
Theme materiality

1 mapped theme

Exposure statements are evidence-qualified. Materiality is only claimed where disclosure supports it.

Women's-health products - contraception (Nexplanon implant), Jada System (postpartum hemorrhage), fertility, plus biosimilars and established (legacy) brands.

Women's health formalization

High by design - Organon was established as a women's-health-focused company (2021 Merck spin-off) - but a large share of revenue comes from established brands and biosimilars rather than the core women's-health growth engine. Current-quarter women's-health franchise revenue was not retrieved this session.

Evidence
No Organon-specific current financials fetched (newsroom URL returned 404/403; SEC filings not retrievable in-session; search budget exhausted). Structural women's-health orientation is well established publicly but current figures are unverified here.
Materiality
estimated — The company is structurally organized around women's health (a named reporting focus since spin-off), supporting an estimated material link; precise current segment figures were not fetched, so it is 'estimated' not 'disclosed'.
Financial evidence

Official SEC filing evidence

Reference period: FY2025.

  • Revenue$6.22 billion
    FY2025[1]
  • Revenue growth-0.0%
    FY2025[1]
  • Diluted EPS$0.72
    FY2025[1]
  • Operating cash flow$700 million
    FY2025[1]
  • Free cash flow$538 million
    FY2025[1]
  • Cash and equivalents$574 million
    FY2025 year-end[1]

Limitation: Filing evidence establishes scale, profitability, cash generation, and leverage. Market-derived valuation is withheld until a licensed market-data feed is connected, and theme materiality is stated separately.

Risks

Material risks and break conditions

Material risks

  • Reimbursement is discretionary and employer/state-budget-dependent; mandate momentum can stall (e.g., a governor vetoed a broader Medicaid fertility mandate) and Medicaid coverage remains rare (only ~3 states).
  • Customer-acquisition costs in direct-to-consumer femtech and virtual care can overwhelm care economics - an explicit thesis-break condition and a real risk for private platforms.

Thesis-break conditions

  • Reimbursement remains weak: state fertility-mandate expansion stalls or retreats and Progyny covered-lives/client growth turns negative for two-plus consecutive quarters.
  • Care economics break: fertility-benefit or digital-platform gross margins compress materially, or Progyny's historically high client retention falls below ~95%, or private femtech marks down on CAC-driven losses.
Investability conclusion

Where the evidence lands

Identity and filing financials are established; theme materiality is stated per the mapped theme assessment. This is a filing-backed research profile with deeper company-specific research pending, and is not a personalized recommendation.

Next diligence

  1. Latest quarterly women's-health revenue (Nexplanon growth trajectory, Jada uptake), fertility contribution, LOE exposure and debt profile.
Source ledger

Identity and evidence sources

Identity was verified against official issuer, filing, exchange, or regulator sources where available.

  1. Organon & Co. FY2025 Form 10-KSEC EDGAR · primary · published 2026-02-24 · accessed 2026-07-22